DaBomb Protein Biotech Corp. (TPEX:6578)
Taiwan · Delayed Price · Currency is TWD 16.65
+0.45 (2.78%)
Oct 8, 2026, 1:30 PM CST
DaBomb Protein Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,198 | 1,374 | 1,334 | 1,251 | 636 | 577 | |
Market Cap Growth | -18.18% | 3.00% | 6.64% | 96.64% | 10.20% | -9.84% |
Enterprise Value | 1,127 | 1,303 | 1,309 | 1,326 | 901 | 687 |
Last Close Price | 16.65 | 19.10 | 19.40 | 20.10 | 14.87 | 16.11 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 114.64 | - | - | - |
PS Ratio | 3.53 | 4.44 | 3.95 | 3.25 | 1.47 | 1.23 |
PB Ratio | 1.19 | 1.39 | 1.23 | 1.31 | 0.88 | 0.86 |
P/TBV Ratio | 1.19 | 1.39 | 1.23 | 1.31 | 0.88 | 0.86 |
P/FCF Ratio | 47.44 | - | 77.04 | - | - | - |
P/OCF Ratio | 29.75 | 82.55 | 28.05 | 192.27 | 32.28 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.32 | 4.21 | 3.87 | 3.45 | 2.08 | 1.46 |
EV/EBITDA Ratio | 43.81 | 124.09 | 125.30 | - | - | - |
EV/FCF Ratio | 44.62 | - | 75.57 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.07 | 0.08 | 0.15 | 0.44 | 0.68 | 0.92 |
Debt / EBITDA Ratio | 2.66 | 5.79 | 14.22 | - | - | - |
Debt / FCF Ratio | 2.71 | - | 9.71 | - | - | - |
Net Debt / Equity Ratio | -0.07 | -0.06 | -0.08 | 0.04 | 0.41 | 0.62 |
Net Debt / EBITDA Ratio | -3.04 | -5.52 | -8.18 | -3.76 | -8.02 | -10.57 |
Net Debt / FCF Ratio | -2.82 | 2.75 | -4.93 | -3.03 | -1050.38 | -1.12 |
Asset Turnover | 0.29 | 0.26 | 0.25 | 0.29 | 0.33 | 0.39 |
Inventory Turnover | 10.06 | 9.05 | 9.91 | 9.26 | 9.16 | 9.62 |
Quick Ratio | 1.98 | 2.06 | 1.61 | 1.21 | 1.07 | 1.14 |
Current Ratio | 2.61 | 2.67 | 3.66 | 2.18 | 1.57 | 1.81 |
Return on Equity (ROE) | -4.11% | -6.67% | 1.14% | -6.77% | -6.37% | -9.09% |
Return on Assets (ROA) | -1.14% | -1.46% | -0.08% | -1.40% | -2.98% | -3.33% |
Return on Invested Capital (ROIC) | -2.29% | -2.91% | -0.13% | -2.96% | -5.89% | -7.00% |
Return on Capital Employed (ROCE) | -2.10% | -2.80% | -0.20% | -2.90% | -5.90% | -5.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -3.50% | -5.05% | 0.87% | -4.56% | -7.02% | -10.82% |
FCF Yield | 2.11% | -1.53% | 1.30% | -0.99% | -0.04% | -65.19% |
Dividend Yield | 2.40% | - | 0.88% | 2.74% | 6.73% | - |
Payout Ratio | - | - | 296.89% | - | - | - |
Buyback Yield / Dilution | -2.28% | -0.11% | -34.30% | -38.27% | -19.16% | 0.13% |
Total Shareholder Return | 0.12% | -0.11% | -33.43% | -35.53% | -12.43% | 0.13% |